The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Microbiome in pharma: bacteriophage therapy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Bacteriophage therapy is a key innovation area in microbiome
Bacteriophage therapy, also known as phage therapy, is a type of treatment that uses naturally occurring viruses called bacteriophages to target and kill harmful bacteria in the body. Bacteriophages are specific to the type of bacteria they target, making them a potential alternative to antibiotics and a promising option for treating bacterial infections.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 75+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of bacteriophage therapy.
Key players in bacteriophage therapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
iNtRON Biotechnology is one of the leading patent filers in bacteriophage therapy. The drug development company focuses on biotechnology and genetic engineering, which can be used to treat human diseases. Its technologies include endolysin, bacteriophage, and biofilm. The company's endolysin technology is an antibiotic substance that destroys the cell walls of bacteria. The company also develops infectious disease drugs. Snipr Technologies and CJ are some of the other key patent filers in bacteriophage therapy.
In terms of application diversity, Nestle leads the pack, while DSM-Firmenich and Intralytix stood in the second and third positions, respectively.
By means of geographic reach, Snipr Technologies held the top position, followed by Phico Therapeutics and Industria Tecnica Farmaceutica.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Microbiome.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
